Business
As a revenue-generating opportunity, occasionally we utilize excess capacity, when available, to provide contract manufacturing and development services to third parties; however, our business development activity is limited in this area.
Longeveron Inc.: Revenue declined 49.9% to $1.199M from $2.392M. Net loss widened to $22.7M from $15.97M. Free cash flow outflow widened to $18.89M from $14.52M. Operating margin contracted 125148 bps to -1942.20%. Longeveron Inc.'s annual comparison also shows the balance-sheet screen falls in the distress range and requires business-model context; the earnings-quality screen is distress.
The read at a glance✓ Audited against SEC data
- Growth — Revenue declined 49.9% to $1.199M from $2.392MWatch
- Profitability — Net loss widened to $22.7M from $15.97MWatch
- Cash flow — Free cash flow outflow widened to $18.89M from $14.52MWatch
- Margins — Operating margin contracted 125148 bps to -1942.20%Watch
- Accounting — Going-concern warningWatch
- Insiders — 2 purchases and 0 salesOK
Where the revenue comes from
Fiscal 2025, as Longeveron Inc. reports it. History and quarterly detail are in the app.
- Clinical Trial Revenue$954K
- Contract Manufacturing Revenue$222K
- Contract Manufacturing Lease Revenue$23K
Leadership changes
From Longeveron Inc.'s own filings, the day they're filed.
- Lisa Locklear · Chief Financial Officer · departureeff. 2026-07-10
- Lisa Locklear · Chief Financial Officer · departureeff. 2026-07-10
- Marie Washburn · Chief Financial Officer · departureeff. 2026-07-10
Latest filings
- 8-K · Company announcement2026-08-24
- 8-K · Company announcement2026-08-19
- 10-Q · Quarterly report2026-08-12
- 8-K · Company announcement2026-08-12
- 8-K · Company announcement2026-07-29
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Longeveron Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.